ÈËÊÂרԱ 4500-5999 ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐÆ¸ > ÈËÊÂרԱ

ÈËÊÂרԱ

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2021-05-31±»ä¯ÀÀ£º1597´Î

4500-5999

²»ÏÞ / ´óר / ÐÔ±ð²»ÏÞ / 1 / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© Éϰà·Ïß²éѯ

ÕÐÆ¸1

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíÈ¨Òæ£¬¾¯ÌèÐé¼ÙÕÐÆ¸,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£º1°´¼Æ»®¿ªÕ¹ÍøÂçÕÐÆ¸£¬Ð£Ô°ÕÐÆ¸£¬É¸Ñ¡¼òÀú£¬½øÐгõÊÔÓ븴ÊÔ°²ÅÅ£»

2¸ºÔðÈÕ³£ÕÐÆ¸ÇþµÀµÄά»¤ÓëְλµÄ¼°Ê±¸üУ»

3¸ºÔðÕÐÆ¸Ð§¹ûµÄ·ÖÎöºÍÕÐÆ¸½á¹ûµÄ¸ú×ٺͷ´À¡£
»4¸ºÔðoffer·¢·Å£¬ÈëÖ°Á÷³ÌµÄ¸ú×ٺͷ´À¡£
»5ЭÖúÉϼ¶×öºÃÔ±¹¤¹ØÏµ¹ÜÀí£»

6Íê³ÉÉϼ¶ÁÙʱ½»°ìµÄÆäËû¹¤×÷ÈÎÎñ¡£
ÈÎÖ°ÒªÇó£º1ÈËÁ¦×ÊÔ´Ïà¹Ø×¨Òµ£¬´óר¼°ÒÔÉÏѧÀú£»

2˼·ÇåÎú£¬¹¤×÷Ö÷¶¯£¬¹µÍ¨±í´ïÄÜÁ¦Ç¿£¬¾ß±¸Á¼ºÃµÄÇ׺ÍÁ¦Ö´ÐÐÁ¦ºÍÍŶӺÏ×÷ÄÜÁ¦£»

3ÊìÁ·ÔËÓó£Óð칫Èí¼þ£¬Ï²»¶ÕÐÆ¸¹¤×÷¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàÆ½·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖÆ±¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖØµãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøÐ¼²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
0¸öÕÐÆ¸Ö°Î»
ְλÃû³Æ£ºÈËÊÂרԱ
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆÖ°Î»
  • ÕÐÆ¸×¨Ô±
    3ǧ-5ǧ/Ô ̩ÖÝ-Ì©ÐË
    ½­ËÕºê»ù»·µç¹É·ÝÓÐÏÞ¹«Ë¾
  • ÈËÊÂרԱ
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    ½­ËÕ¶¦ÍúÒ±½ð²ÄÁÏÓÐÏÞ¹«Ë¾
  • ÈËÊÂרԱ
    3ǧ8-4ǧ5/Ô ̩ÖÝ-Ì©ÐË
    ½­ËÕÖÜÄ©ºÜæʳƷ¿Æ¼¼ÓÐÏÞ¹«Ë¾